Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

https://www.intensive.org/

30. November 2018

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

30. November 2018

Search for:

Adrenomed closes € 24 M financing led by Wellington and HBM

26. November 2018

Adrenomed AG reveals Adrecizumab mode of action

14. June 2018

Clinical Phase II started: Adrenomed doses first patient in proof-of-concept study with Adrecizumab

11. December 2017

Researchers to Present New Preclinical and Clinical Data on Lead Candidate Adrecizumab at Upcoming ESICM (European Society of Intensive Care Medicine) Conference

25. September 2017

Adrenomed AG receives approval to conduct proof of concept study with Adrecizumab to treat patients with early septic shock

11. August 2017

Adrecizumab is safe, well tolerated and shows additional therapeutic potential in acute heart failure

8. March 2017

More News

Recent Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

30. November 2018

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

30. November 2018

More Events

CONTACT

Contact Info

+49 (0) 3302 20 77 8 0
+49 (0) 3302 20 77 8 15
info@adrenomed.com

ADRENOMED AG

Neuendorfstraße 15A
Hennigsdorf b. Berlin
D-16761, Germany.

Twitter Linkedin

Name

Subject

Message

I agree to the usage and processing of my personal data

Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

Recent News

Adrenomed closes € 24 M financing led by Wellington and HBM

Adrenomed AG reveals Adrecizumab mode of action

Clinical Phase II started: Adrenomed doses first patient in proof-of-concept study with Adrecizumab

Researchers to Present New Preclinical and Clinical Data on Lead Candidate Adrecizumab at Upcoming ESICM (European Society of Intensive Care Medicine) Conference

Adrenomed AG receives approval to conduct proof of concept study with Adrecizumab to treat patients with early septic shock

Adrecizumab is safe, well tolerated and shows additional therapeutic potential in acute heart failure

Recent Events

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19.-22, 2019 Brussels, Belgium

JPM Healthcare Conference, San Francisco, 7.-10.01.2019

Archive

CONTACT

Contact Info